-
European Commission Approves Merck’s KEYTRUDA® Plus Chemotherapy for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
28 Mar 2024 22:07 GMT
… for patients with metastatic lung cancer, lung cancer continues to be the … -small cell lung cancer at high risk of recurrence, regardless of … in earlier stages of lung cancer,” said Marjorie Green, … drive earlier diagnoses of lung cancer, an urgent need.”
…
-
EU Approves Merck’s Keytruda, Chemo Combo for Lung Cancer
28 Mar 2024 17:45 GMT
… resectable non-small cell lung cancer first as a neoadjuvant … in non-small cell lung cancer (NSCLC). The new … approval for Keytruda in lung cancer in Europe.”
Europe’s … disease recurrence, progression or death.
Despite advancements, lung cancer continues …
-
Merck’s Keytruda regimen granted EC approval for expanded lung cancer use
28 Mar 2024 13:04 GMT
… Keytruda (pembrolizumab) for expanded lung cancer use.
The decision, which … small cell lung cancer (NSCLC) at high risk of recurrence, means … approval marks the sixth lung cancer indication in Europe for … in earlier stages of lung cancer”.
She continued: “We …
-
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
28 Mar 2024 11:00 GMT
… patients with metastatic lung cancer, lung cancer continues to … cell lung cancer at high risk of recurrence, … cycles.
About lung cancer
Lung cancer is the leading … lung cancer globally. Non-small cell lung cancer is the most common type of lung cancer …
-
EC approves Merck’s KEYTRUDA regimen for NSCLC treatment
29 Mar 2024 09:46 GMT
… non-small cell lung cancer (NSCLC) at increased recurrence risk.
This … decrease in the disease recurrence, progression, or mortality … treatments in earlier stages of lung cancer.
“We are eager … help drive earlier diagnoses of lung cancer, an urgent need.”
…
-
A Combined Measure of the Triglyceride Glucose Index and Trimethylamine N-Oxide in Risk Stratification of ST-Segment Elevation Myocardial Infarction Patients with High-Risk Plaque Features Defined by Optical Coherence Tomography: A Substudy of the…
29 Mar 2024 06:30 GMT
… ischemic cerebrovascular events and revascularization. Recurrence MI was diagnosed as positive … (including all-cause death, MI recurrence, ischemic stroke and revascularization) well … non-squamous Non-small Cell Lung Cancer (NSCLC) patients treated with …
-
New study shows association of historical housing discrimination and shortfalls in colon cancer treatment
28 Mar 2024 22:25 GMT
… reduce the chance of disease recurrence.
Compared with newly diagnosed colon … increased incidence of advanced-stage lung cancer in formerly redlined areas of … and a lower odds of lung cancer screening for Black individuals in …
-
Pembrolizumab/Chemo Earns European Approval in Resectable NSCLC
28 Mar 2024 20:39 GMT
… cell lung cancer (NSCLC) who are at high risk of recurrence, … for patients with metastatic lung cancer, lung cancer continues to be the … small cell lung cancer (NSCLC) at high risk of recurrence in … for resectable non-small cell lung cancer. News release. FDA. …
-
The Potential of FOXP3 in Predicting Survival and Treatment Response in Breast Cancer
28 Mar 2024 13:57 GMT
… FOXP3 was linked to extended recurrence-free survival (RFS), while … ,27 non-small cell lung cancer,18 oral,28 prostate, … READ, Rectum adenocarcinoma; RFS, Recurrence-free survival; ROC, Receiver Operating … data in non-small-cell lung cancer. PLoS One. 2013;8 …
-
Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024
28 Mar 2024 11:00 GMT
… KRASG12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with … to promote resistance and tumor recurrence. In addition, synergistic effect … KRASG12Cand KRAS KRASG12D inhibitors in lung cancer and pancreatic cancers, respectively, …